Analysts predict that Johnson & Johnson (NYSE:JNJ) will announce earnings per share of $1.98 for the current quarter, according to Zacks Investment Research. Four analysts have provided estimates for Johnson & Johnson’s earnings, with the highest EPS estimate coming in at $2.10 and the lowest estimate coming in at $1.86. Johnson & Johnson reported earnings per share of $2.12 in the same quarter last year, which suggests a negative year over year growth rate of 6.6%. The company is scheduled to issue its next quarterly earnings results before the market opens on Tuesday, October 13th.
According to Zacks, analysts expect that Johnson & Johnson will report full year earnings of $7.85 per share for the current financial year, with EPS estimates ranging from $7.75 to $7.95. For the next fiscal year, analysts forecast that the business will report earnings of $8.94 per share, with EPS estimates ranging from $8.48 to $9.45. Zacks’ EPS averages are a mean average based on a survey of sell-side research firms that that provide coverage for Johnson & Johnson.
Johnson & Johnson (NYSE:JNJ) last released its earnings results on Thursday, July 16th. The company reported $1.67 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $1.50 by $0.17. The firm had revenue of $18.34 billion for the quarter, compared to the consensus estimate of $17.73 billion. Johnson & Johnson had a return on equity of 35.21% and a net margin of 22.69%. The firm’s revenue for the quarter was down 10.8% compared to the same quarter last year. During the same period in the prior year, the business posted $2.58 earnings per share.
JNJ has been the topic of a number of recent research reports. Stifel Nicolaus cut Johnson & Johnson from a “buy” rating to a “hold” rating in a report on Wednesday, August 19th. Citigroup lifted their price objective on Johnson & Johnson from $165.00 to $170.00 and gave the company a “buy” rating in a research report on Friday, July 17th. Independent Research raised Johnson & Johnson from a “hold” rating to a “buy” rating and lifted their price objective for the company from $161.00 to $164.00 in a research report on Monday, July 20th. Bank of America reissued a “buy” rating on shares of Johnson & Johnson in a research report on Monday, July 20th. Finally, SVB Leerink reissued an “outperform” rating on shares of Johnson & Johnson in a research report on Wednesday, July 15th. One analyst has rated the stock with a sell rating, five have assigned a hold rating and eleven have given a buy rating to the stock. The company has a consensus rating of “Buy” and a consensus target price of $163.00.
In other news, EVP Kathryn E. Wengel sold 16,115 shares of Johnson & Johnson stock in a transaction dated Wednesday, September 2nd. The stock was sold at an average price of $153.52, for a total value of $2,473,974.80. Following the transaction, the executive vice president now directly owns 66,658 shares in the company, valued at $10,233,336.16. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, EVP Ashley Mcevoy sold 29,000 shares of Johnson & Johnson stock in a transaction dated Tuesday, July 28th. The stock was sold at an average price of $147.47, for a total value of $4,276,630.00. Following the completion of the transaction, the executive vice president now owns 21,682 shares in the company, valued at $3,197,444.54. The disclosure for this sale can be found here. Insiders own 0.27% of the company’s stock.
Several institutional investors have recently bought and sold shares of JNJ. Sofos Investments Inc. increased its stake in Johnson & Johnson by 172.0% during the first quarter. Sofos Investments Inc. now owns 1,148 shares of the company’s stock valued at $33,000 after acquiring an additional 726 shares during the period. Altshuler Shaham Ltd bought a new position in Johnson & Johnson during the first quarter valued at about $35,000. Lake Point Wealth Management increased its stake in Johnson & Johnson by 144.4% during the first quarter. Lake Point Wealth Management now owns 286 shares of the company’s stock valued at $38,000 after acquiring an additional 169 shares during the period. Islay Capital Management LLC bought a new position in Johnson & Johnson during the second quarter valued at about $42,000. Finally, FAI Wealth Management increased its stake in Johnson & Johnson by 45.9% during the second quarter. FAI Wealth Management now owns 321 shares of the company’s stock valued at $45,000 after acquiring an additional 101 shares during the period. Institutional investors and hedge funds own 67.44% of the company’s stock.
JNJ traded down $1.08 during trading hours on Monday, hitting $146.24. The company’s stock had a trading volume of 5,485,602 shares, compared to its average volume of 8,360,347. Johnson & Johnson has a fifty-two week low of $109.16 and a fifty-two week high of $157.00. The firm has a market capitalization of $385.02 billion, a PE ratio of 21.38, a PEG ratio of 3.29 and a beta of 0.68. The company has a 50-day simple moving average of $149.19 and a 200 day simple moving average of $144.96. The company has a current ratio of 1.25, a quick ratio of 0.99 and a debt-to-equity ratio of 0.40.
The business also recently announced a quarterly dividend, which was paid on Tuesday, September 8th. Shareholders of record on Tuesday, August 25th were issued a dividend of $1.01 per share. The ex-dividend date was Monday, August 24th. This represents a $4.04 annualized dividend and a yield of 2.76%. Johnson & Johnson’s dividend payout ratio (DPR) is currently 46.54%.
About Johnson & Johnson
Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the health care field worldwide. It operates in three segments: Consumer, Pharmaceutical, and Medical Devices. The Consumer segment offers baby care products under the JOHNSON'S brand; oral care products under the LISTERINE brand; beauty products under the AVEENO, CLEAN & CLEAR, DABAO, JOHNSON'S Adult, LE PETITE MARSEILLAIS, NEUTROGENA, and OGX brands; over-the-counter medicines, including acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; and acid reflux products under the PEPCID brand.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.